Search Results
Your search for The A,The A matches 32366 pages
Showing 26601 - 26650One Step Forward
ASCO has taken the field of psychosocial oncology a step forward in the right direction by providing guidelines for oncologists to direct care of the two most common emotional symptoms that patients experience: anxiety and depression.1 It is fair to say that all patients experience these...
ASCO Releases Adapted Guideline on Screening, Assessment, and Care of Anxiety and Depressive Symptoms in Adults With Cancer
Detection of depression is suboptimal, and its severity is underestimated in the general population, but it is known psychiatric disorders are more common in patients with cancer than in those with any other chronic illness. Although studies in cancer patients have yielded varying figures, it is...
Challenges in Creating and Promoting Clinical Practice Guidelines
With regard to clinical practice guidelines, clinicians want an authoritative resource that will clearly and concisely instruct them in most clinical scenarios. Guideline developers want to give them this, “but producing guidelines is not as straightforward as it might seem,” according to David...
The Affordable Care Act: NCCN Panelists Rate It ‘Average’
Oncologists and third-party payers are already experiencing changes as a result of the Affordable Care Act, which earned an “average” rating by a panel of providers, payers, and patients assembled at the 19th Annual Conference of the National Comprehensive Cancer Network (NCCN) in Hollywood,...
Andrew D. Zelenetz, MD, PhD, on Treating the Elderly Lymphoma Patient With Elevated Bilirubin
At the 19th Annual Conference of the National Comprehensive Cancer Network (NCCN), lymphoma expert and NCCN Panel Chair on Lymphoma, Andrew D. Zelenetz, MD, PhD, fielded questions from oncologists. The ASCO Post was there to capture his recommendations for a common clinical scenario—treating the...
Belinostat Moves Forward in Trials for Two Aggressive Cancers
In February, the U.S. Food and Drug Administration (FDA) granted belinostat (Beleodaq), a targeted histone deacetylase (HDAC) inhibitor, priority review status based on a pivotal phase II trial in peripheral T-cell lymphoma. Just 1 month later, researchers at the National Cancer Institute (NCI) in...
Workshops Train Community Cancer Center Nurses and Administrators to Implement Clinical Trials
A series of new workshops are teaching nurses and administrators from community hospital cancer programs how to promote, run, and improve their institutions’ clinical trials. The training focuses on specific skills and tasks, offers postcourse support and aims for long-term, measurable outcomes,...
Promoting Health Behaviors Among Cancer Survivors
Promoting healthy behaviors among cancer survivors is associated with improved quality of life according to many studies. But how to translate that evidence into community practice remains a huge question, and the need for answers is growing. It’s not only the lack of consensus on how to help...
Expert Point of View: Edith Perez, MD
Commenting on the I-SPY 2 neratinib results presented at the 2014 American Association for Cancer Research Annual Meeting, Edith Perez, MD, Deputy Director at Large, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida, said that results were consistent with other data. “Testing for HER2...
I-SPY 2 Trial ‘Graduates’ Neratinib to Phase III Study in HER2-Positive, Hormone Receptor–Negative Breast Cancer
In the targeted-therapy era, it is important to identify subsets of patients who can benefit from novel agents and combinations as quickly as possible. The I-SPY 2 trial is designed to expedite this goal and to change the way that targeted agents are studied and approved. This innovative adaptive...
Expert Point of View: Paul K. Paik, MD
FGFR abnormalities have been reported in many cancers, including breast, lung, and bladder cancers. While the types of events that occur in these cancers are different, preclinical evidence supports a role for oncogenesis in each of these types,” said formal discussant of the FGFR inhibitor studies ...
FGFR Inhibitors of Interest in Bladder and Lung Cancer
Fibroblast growth factor receptor (FGFR) inhibitors are an emerging area of interest in cancer therapeutics. Studies presented at the 2014 American Association for Cancer Research (AACR) Annual Meeting in San Diego provided early encouraging data for two investigational pan-FGFR inhibitors for the...
Expert Point of View: John C. Byrd, MD
Formal discussant of the AG-221 study presented at the 2014 American Association for Cancer Research meeting, John C. Byrd, MD, of The Ohio State University, Columbus, said, “Congratulations to Dr. Stein for bringing this drug forth.” He continued, “Acute myeloid leukemia (AML) is challenging to...
Early Data for AG-221 Show Unprecedented Activity in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Although the data are preliminary, experts were impressed with responses to a novel IDH2 inhibitor called AG-221 in patients with hematologic malignancies. In the first clinical trial of AG-221, there were three complete remissions, two complete remissions with incomplete platelet count recovery...
Expert Point of View: Daniel Petrylak, MD
This is an extremely important study,” said Daniel Petrylak, MD, Professor of Medicine and Urology at the Yale School of Medicine in New Haven, Connecticut. “This work needs to be replicated prospectively in a larger group of patients. Right now we have no way to select appropriate first-line...
Blood Test Can Identify Prostate Cancer Patients Who Are Not Likely to Respond to Enzalutamide
A simple blood test may be able to identify men with castration-resistant prostate cancer who will not respond to enzalutamide (Xtandi). The presence of the splice variant androgen receptor (AR) V7 in circulating tumor cells identified men who were unlikely to respond to enzalutamide and whose...
Lymphedema Lingers Long After Sentinel Lymph Node Dissection for Early Breast Cancer
Patients with early-stage breast cancer who underwent sentinel lymph node dissection experienced lymphedema with increasing incidence over time, according to a presentation at the 2014 Society of Surgical Oncology (SSO) Cancer Symposium in Phoenix.1 In women who took part in the American College of ...
FDA Approves Ramucirumab for Stomach Cancer
The U.S. Food and Drug Administration (FDA) has approved ramucirumab (Cyramza) to treat patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with disease progression on or after prior treatment with fluoropyrimidine- or platinum-containing chemotherapy....
Survival Analysis of Contralateral Prophylactic Mastectomy Sparks Discussion
Contralateral prophylactic mastectomy improved breast cancer patients’ odds of overall survival by 23% compared with single mastectomy alone, according to a retrospective analysis of nearly 170,000 patients in a U.S. database, but surgical breast cancer specialists warned that the data needed to be ...
NCCN Clinical Practice Guidelines in Oncology: 2014 Updates
At the 19th Annual Conference of the National Comprehensive Cancer Network (NCCN), held recently in Hollywood, Florida, NCCN Panel members presented updates for several tumor types, briefly summarized here. For a more complete description of all updates, visit www.nccn.org. Breast Cancer Guidelines ...
Reflecting on the Past Year and Looking Ahead to the Next
On assuming the Presidency of ASCO a year ago, I recognized that one of our greatest challenges as a professional society is helping the American public understand the value of cancer research, especially now, when scientific advances are accelerating but resources are contracting. This is partly...
ASCO Develops New Strategy to Increase Value in Cancer Care
Last January, ASCO held a leadership summit in Washington, DC, with representatives from the pharmaceutical industry, insurance payers, patient advocates, and physicians to address the skyrocketing costs of new drugs and technologies used in the diagnosis and treatment of cancer. Although costs are ...
Guidelines for Chemotherapy-Induced Neuropathy: The Known Unknowns
It is a tribute to the advances in supportive care that peripheral neuropathy, along with fatigue, has become the most vexing management challenge in cancer patients receiving chemotherapy. The successes of modern antiemetic regimens and white blood cell growth factor support have radically altered ...
ASCO Releases Guideline on Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers
ASCO has released a clinical practice guideline on prevention and treatment of chemotherapy-induced peripheral neuropathy in adult cancer patients, published in the Journal of Clinical Oncology.1 The guidelines resulted from the efforts of an expert panel, with representation from the fields of...
About the Artist
Keith Witmer received his Bachelor’s degree in Fine Arts from Otis/Parsons School of Design. He subsequently launched his career in advertising and publication with a commanding presence, initially using pen and ink and scratchboard mediums. Working with clients such as FedEx, Apple Computer,...
About the Writer
Ronald Piana is an independent writer and reporter with more than 15 years of experience in oncology communications and publishing. In addition to the profiles published in this special anniversary issue of The ASCO Post, Ron has written more than 100 articles, interviews, and profiles for leading...
Ernest Louis Mazzaferri, Sr, MD: September 27, 1936–May 14, 2013
Ernest Louis Mazzaferri, Sr, MD, MACP, of Henderson, Nevada, passed away peacefully at home on May 14, 2013 after a short illness, surrounded by his family. He was born September 27, 1936 in Cleveland, Ohio. Dr. Mazzaferri spent most of his medical career at The Ohio State University, serving as...
Jane Weeks, MD, MSc: August 12, 1952–September 10, 2013
On September 10, 2013, Jane Carrie Weeks, MD, MSc, a prominent researcher at Dana-Farber Cancer Center, died of cancer in her Boston home. She was 61. At the time of her death, Dr. Weeks was Professor of Medicine at Harvard Medical School, Professor of Health Policy and Management at the Harvard...
Janet L. Rowley, MD: April 5, 1925–December 17, 2013
Dr. Janet L. Rowley’s groundbreaking research in the translocation of genetic material bucked scientific convention and heralded a new understanding that cancer is indeed a genetic disease. Her research was largely responsible for the discoveries that led to the development of the targeted cancer...
Geoffrey P. Herzig, MD: December 6, 1941–December 20, 2013
Many of the advances that have bettered mankind are attributed to those who were driven by a primary passion. Geoffrey P. Herzig, MD, lived the better part of his life with a primary passion: conducting research to increase the cure rate of leukemia and lymphoma patients. His friend and colleague,...
Donald L. Morton, MD: September 12, 1934–January 10, 2014
Donald L. Morton, MD, transformed the management of melanoma and breast cancer by introducing the sentinel node biopsy, giving surgeons an accurate roadmap for treatment, and sparing generations of cancer patients from the morbidity associated with unnecessary surgery. Throughout his distinguished...
Peter Jacobs, MD, PhD: 1934–2013
Peter Jacobs, MD, PhD, regarded as the father of hematology in his native country of South Africa, began each day at 3 AM in the gym. During his workout, Dr. Jacobs would routinely call the nursing staff for updates on patients in his ward. Before sunup, Dr. Jacobs was on his way to the hospital....
ASCO’s Visionary Founders
On April 9, 1964, seven physicians—Jane Cooke Wright, MD, FASCO; Arnoldus Goudsmit, MD, PhD; Fred J. Ansfield, MD, FASCO; Harry F. Bisel, MD, FASCO; Herman H. Freckman, MD, FASCO; Robert W. Talley, MD, FASCO; and William Wilson, MD, FASCO—met for lunch at the Edgewater Beach Hotel in Chicago. They...
Recipients of the David A. Karnofsky Memorial Award and Lecture
2014: H.M. (Bob) Pinedo, MD, PhD 2013: Martine J. Piccart, MD, PhD 2012: Kanti R. Rai, MD 2011: Kenneth Anderson, MD 2010: Daniel D. Von Hoff, MD, FACP 2009: Clara D. Bloomfield, MD 2008: V. Craig Jordan, OBE, PhD, DSc 2007: Robert A. Kyle, MD, MACP 2006: Dennis J. Slamon, MD, PhD 2005: Charles L....
David A. Karnofsky: The Man Behind the Karnofsky Memorial Award and Lecture
David A. Karnofsky, MD, dedicated himself to the pursuit of scientific excellence and the investigation of more effective therapies for cancer for nearly 30 years, from the time he was a young resident at the Collis P. Huntington Memorial Hospital for Cancer Research of Harvard University, until...
Understanding the Relationship Between the Lab and the Clinic is Key to 2014 Karnofsky Memorial Award Honoree’s Success
The island nation of Curaçao is nestled in the southern Caribbean Sea off the Venezuelan coast. Curaçao was first settled by the Arawaks, an Amerindian people that inhabited the island for hundreds of years before the arrival of Europeans. Amid one wave of settlers from Portugal and Spain that...
Enthusiasm and Vision Guide the Head of FDA’s Oncology Office
In 2005, Richard Pazdur, MD, was named the FDA’s Director of the Office of Hematology and Oncology Products. By any measure, being arbiter of the nation’s oncology drug pipeline is a daunting prospect, but Dr. Pazdur sees it as an opportunity to encourage his talented staff to work for the greater ...
Internationally Renowned Oncologist Blazes a Trail in Breast Cancer Genetics and Risk Assessment
Olufunmilayo Falusi Olopade, MD, FACP, the daughter of an Anglican pastor, was born in Nigeria. Dr. Olopade’s interest in oncology first surfaced while in medical school at the University College Hospital in Ibadan, where she helped care for patients with Burkitt’s lymphoma, which is common in...
Nationally Renowned Surgeon and Researcher, John E. Niederhuber, MD, Relishes the Challenges That Lie Ahead
John E. Niederhuber, MD, was born and grew up in Steubenville, Ohio, a steel mill town located along the Ohio River. Dr. Niederhuber had a childhood interest in engineering and chemistry, but it was the town’s general practitioner who made a lasting impact on his career path. “He was an old-style...
Barbara L. McAneny, MD, Is Dedicated to Designing a Better Health-Care System
Barbara L. McAneny, MD, grew up on the outskirts of Alton, a small city on the Mississippi River in Madison County, Illinois. It is an area rich in history, famous as the site of Abraham Lincoln and Stephen Douglas’s last debate and for its role preceding and during the American Civil War. “We...
A Coast-to-Coast Road to an Illustrious Career in Radiation Oncology
Nationally regarded radiation oncologist and lymphoma expert Richard Hoppe, MD, was reared in Seaford, a small town hugging the South Shore of Long Island, New York. “I grew up in the early part of Long Island’s suburban sprawl, and my childhood was a fairly typical experience for that time,”...
ASCO Past President and Breast Cancer Researcher Works to Unite the Oncology Community in the Fight Against Cancer
World-renowned breast cancer researcher, Nancy E. Davidson, MD, was born in Denver, Colorado, the daughter of two geologists. “My mother was a geologist beginning in the 1940s, a time when women really didn’t pursue that kind of career. So, I was reared in a very scientifically oriented...
International Leader in Multiple Myeloma Was Inspired by an Early Mentor’s Lessons in Wisdom and Compassion
Kenneth C. Anderson, MD, grew up in Auburn, a small historic town in central Massachusetts that was settled by the English in 1714. His desire to become a doctor bloomed early. “My decision to possibly pursue a career in medicine was first inspired by my mother, who was a registered nurse, and by...
An Early Calling to Medicine That Never Wavered: ASCO President Peter P. Yu, MD
The road leading to a career in medicine is often a stepwise journey of multiple decision points and influences. However, sometimes the decision to become a doctor is hardwired from birth. Such was the case with 2014-2015 ASCO President Peter P. Yu, MD. Since his days in nursery school, Dr. Yu...
Remembering Selma Ruth Schimmel
My last conversation with Selma Schimmel was 2 months ago. She had been uncharacteristically out of touch for a few weeks, and I had a nagging feeling the severe pain in her psoas muscle caused by advancing ovarian cancer—which had plagued her for months and she described as in a “league of its...
Congress Celebrates 50 Years of ASCO: Special Order on House Floor Honors Society’s Mid-Century Anniversary
The U.S. House of Representatives recently held a Special Order in honor of the American Society of Clinical Oncology (ASCO) as it celebrates its 50th anniversary. During the event on the House floor, Members of Congress highlighted critical advancements in cancer care over the past 50 years and...
For Hospitalized Cancer Patients, Thromboprophylaxis Often Prescribed Without Regard to Risk Factors
Pharmacologic thromboprophylaxis is commonly prescribed to hospitalized patients with cancer without regard to concomitant risk factors for venous thromboembolism, according to a prospective, cross-sectional study of patients with cancer at five academic medical centers. Results were reported in...
Cancer Patients at High Recurrence Risk for Venous Thromboembolism Should Be Considered for Secondary Prophylaxis
The risk of recurrence of venous thromboembolism in cancer patients can be stratified. “In particular, patients with brain, lung, stage IV pancreatic or ovarian cancer, myeloproliferative or myelodysplastic disorders, [other] stage IV cancer, cancer stage progression or leg paresis have the highest ...
Increased Hospice Use Among Minority Patients Treated in Provider-Based Research Networks
Minority patients with lung cancer who receive treatment in practices affiliated with provider-based research networks “have greater hospice enrollment than those treated in academic and community practices,” concluded Dolly C. Penn, MD, MSCR, and colleagues at the University of North Carolina...
Encourage Questions and Actions About the High Cost of Cancer Drugs
Physicians are now more likely to discuss cancer drug prices, “which was a rarity in the past,” Hagop M. Kantarjian, MD, told The ASCO Post. “Oncologists are starting to incorporate the price as a side effect, because if the price is too high, that is a financial side effect to patients, who can go ...
